BONUSCAP-ZERTIFIKAT - ELI LILLY & CO | Real-time BOERSE MUENCHEN 01:16:46 04/06/2024 am IST | ||
| 1,094 EUR | +1.20% |
|
| 1 month | +7.54% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 04/24/04 | 1,094 | +1.20% |
| 31/24/31 | 1,081 | +0.68% |
| 30/24/30 | 1,074 | +0.88% |
| 29/24/29 | 1,064 | +0.83% |
| 28/24/28 | 1,056 | -0.94% |
Real-time BOERSE MUENCHEN
Last update June 04, 2024 at 01:16 am IST
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD3TAB |
| ISIN | DE000HD3TAB9 |
| Date issued | 18/03/2024 |
| Strike | 1,250 $ |
| Maturity | 20/12/2024 (200 Days) |
| Parity | 1 : 1 |
| Emission price | 927.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1,097 € |
|---|---|
| Lowest since issue | 850.4 € |
| Spread | 0.13 € |
| Spread % | 0.01% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
- Stock Market
- Certificates
- Certificat
